Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What is the Impact of Treatment De-Escalation on Patient Reported Outcomes in Patients with T1-T2 Oropharyngeal Cancers? A Secondary Analysis of the ORATOR Studies.

International journal of radiation oncology, biology, physics·2026
Same author

Duration of systemic therapy in patients with metastatic <i>EGFR</i>-mutated non-small cell lung cancer and brain metastases.

Translational lung cancer research·2026
Same author

Investigating Setup Error Differences between Conventional and Ultra-Hypofractionated Whole Pelvis Radiation Therapy: A Secondary Analysis from the HOPE Randomized Clinical Trial.

Journal of applied clinical medical physics·2026
Same author

Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Adenocarcinoma: A Systematic Review and Meta-Analysis of Prospective Trials.

Practical radiation oncology·2026
Same author

Water Insecurity, Social Perspectives, and Health Impacts in Private Drinking Water Sources in Pennsylvania: Two Systematic Literature Reviews.

WIREs. Water·2026
Same author

Re-evaluating previous dose and allowing increasing recovery (REPAIR): study protocol for a thoracic reirradiation phase I dose escalation trial.

BMC cancer·2026
Same journal

Characteristics and Clinical Outcomes of De Novo and Acquired Uncommon Compound EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer: A Brief Report.

Clinical lung cancer·2026
Same journal

Dosimetric Predictors of Radiation Pneumonitis for Stage III NSCLC Treated With Neoadjuvant Immuno-chemotherapy and Definitive Chemoradiation: A Multi-institutional Analysis.

Clinical lung cancer·2026
Same journal

Durvalumab After Chemoradiotherapy for Locally Advanced NSCLC: A Real-World Analysis Using a Nationwide Claims Database in Japan.

Clinical lung cancer·2026
Same journal

Radiological Predictors of Visceral Pleural Invasion in Lung Cancers With Ground-Glass Opacity and Pleural Contact.

Clinical lung cancer·2026
Same journal

CHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural Mesothelioma.

Clinical lung cancer·2026
Same journal

Complete Spontaneous Regression of Lung Adenocarcinoma With No Residual Malignancy After Surgical Resection: A Case Report.

Clinical lung cancer·2026
See all related articles
  1. Home
  3. Off-protocol Radiotherapy In Prospective Systemic Therapy Trials For Metastatic Non-small Cell Lung Cancer.
  1. Home
  3. Off-protocol Radiotherapy In Prospective Systemic Therapy Trials For Metastatic Non-small Cell Lung Cancer.

Related Experiment Video

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Off-Protocol Radiotherapy in Prospective Systemic Therapy Trials for Metastatic Non-Small Cell Lung Cancer.

Kara M Ruicci1, George J Li1, Andrew Warner2

  • 1Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.

Clinical Lung Cancer
|June 18, 2026

View abstract on PubMed

Summary
This summary is machine-generated.

Radiotherapy use is common in metastatic non-small cell lung cancer (NSCLC) trials, but details are inconsistently reported. Future trials need clear radiation parameters to improve data accuracy and patient outcomes.

Keywords:
Clinical trialImmunotherapyNSCLCRadiationTargeted therapy

Related Experiment Videos

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Area of Science:

  • Oncology
  • Clinical Trials
  • Radiation Oncology

Background:

  • Radiotherapy is frequently used for metastatic non-small cell lung cancer (NSCLC) to manage symptoms and treat metastases.
  • Emerging evidence suggests radiotherapy can influence the course of metastatic NSCLC.

Purpose of the Study:

  • To examine protocol specifications for radiation use in prospective systemic therapy trials for metastatic NSCLC.
  • To assess the documentation of radiation exposure before and during trial enrollment.

Main Methods:

  • A systematic review of completed phase II-IV systemic therapy trials for metastatic NSCLC was conducted using ClinicalTrials.gov.
  • Descriptive statistics were used to summarize trial characteristics, and Fisher's exact test/logistic regression analyzed associations between radiation allowance and trial outcomes.

Main Results:

  • Of 79 included trials, most were phase III, randomized, and unmasked, targeting PD-1/PD-L1, EGFR, or VEGF.
  • While most trials allowed prior radiation, few specified washout periods or prohibited concurrent radiation.
  • No studies detailed radiation parameters for off-protocol use, and its allowance was not linked to trial success.

Conclusions:

  • Prospective systemic therapy trials for NSCLC often lack consistent reporting of radiotherapy details.
  • Clear guidelines for radiation use before and during trials are essential due to overlapping toxicities and radiotherapy's common application in NSCLC.